AR127945A1 - Formulaciones farmacéuticas que comprenden un agonista del receptor de amilina, un agonista del receptor de glp-1 y una ciclodextrina - Google Patents

Formulaciones farmacéuticas que comprenden un agonista del receptor de amilina, un agonista del receptor de glp-1 y una ciclodextrina

Info

Publication number
AR127945A1
AR127945A1 ARP220103410A ARP220103410A AR127945A1 AR 127945 A1 AR127945 A1 AR 127945A1 AR P220103410 A ARP220103410 A AR P220103410A AR P220103410 A ARP220103410 A AR P220103410A AR 127945 A1 AR127945 A1 AR 127945A1
Authority
AR
Argentina
Prior art keywords
receptor agonist
glp
cyclodextrin
pharmaceutical formulations
amylin
Prior art date
Application number
ARP220103410A
Other languages
English (en)
Spanish (es)
Inventor
Rosa Rebecca Erritze Hansen
Stig Christoffersen
Benjamin Kjeldsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority to PCT/EP2023/058317 priority Critical patent/WO2023187067A1/fr
Publication of AR127945A1 publication Critical patent/AR127945A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/225Calcitonin gene related peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP220103410A 2021-12-13 2022-12-13 Formulaciones farmacéuticas que comprenden un agonista del receptor de amilina, un agonista del receptor de glp-1 y una ciclodextrina AR127945A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2023/058317 WO2023187067A1 (fr) 2022-03-30 2023-03-30 Procédé de formulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21214004 2021-12-13
EP22191564 2022-08-22

Publications (1)

Publication Number Publication Date
AR127945A1 true AR127945A1 (es) 2024-03-13

Family

ID=84819844

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103410A AR127945A1 (es) 2021-12-13 2022-12-13 Formulaciones farmacéuticas que comprenden un agonista del receptor de amilina, un agonista del receptor de glp-1 y una ciclodextrina

Country Status (3)

Country Link
AR (1) AR127945A1 (fr)
TW (1) TW202339788A (fr)
WO (1) WO2023110833A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US8389472B2 (en) * 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
WO2008073448A2 (fr) * 2006-12-12 2008-06-19 Amylin Pharmaceuticals, Inc. Formulations pharmaceutiques et leurs procédés de production
KR102066987B1 (ko) 2011-06-10 2020-01-16 노보 노르디스크 에이/에스 폴리펩티드
EP3858373A1 (fr) * 2020-01-31 2021-08-04 Adocia Compositions comprenant au moins un agoniste au récepteur de l'amyline et un agoniste du récepteur glp-1
TW202227474A (zh) 2020-12-18 2022-07-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1及澱粉素受體之共促效劑

Also Published As

Publication number Publication date
TW202339788A (zh) 2023-10-16
WO2023110833A1 (fr) 2023-06-22

Similar Documents

Publication Publication Date Title
CL2021001332A1 (es) Agonistas de glp-1r y usos de los mismos.
BR112022013746A2 (pt) Formulação aquosa de cagrilintida, formulação aquosa de semaglutida, dispositivo médico, e, combinação de dose fixa
BR112018008805A2 (pt) proteínas de função dupla e composição farmacêutica que compreende a mesma
SV2017005539A (es) Composiciones farmaceuticas para terapia combinada
MX2023008854A (es) Agonistas del receptor acoplado a proteinas g (gpcr), composiciones farmaceuticas que los comprenden y metodos para su uso.
BR112021022335A2 (pt) Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer
BR112015010203A8 (pt) composição para a prevenção ou tratamento de diabetes, complicações diabéticas ou diabesidade, uso de um conjugado análogo da oxintomodulina, e, método para a preparação de um conjugado análogo da oxintomodulina
BR112022003589A2 (pt) Conjugado de anticorpo-fármaco compreendendo anticorpo contra ror1 humano e uso para o mesmo
CO2023008866A2 (es) Coagonistas de los receptores de glp-1 y amilina
MX2022015500A (es) Farmaco profilactico y terapeutico para enfermedad de higado graso no alcoholico.
PH12019502655A1 (en) Acylated insulin compound
Forbes et al. Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides
BR112014031649A2 (pt) composto representado pela fórmula 1 tendo a enzima inibidora de atividade 11b-hsd1; método para sua produção e composição farmacêutica contendo o mesmo como ingrediente ativo
BR112023019967A2 (pt) Composto de tetra-hidronaftaleno e método de preparação para o mesmo e uso do mesmo em medicina
AR127945A1 (es) Formulaciones farmacéuticas que comprenden un agonista del receptor de amilina, un agonista del receptor de glp-1 y una ciclodextrina
Esser et al. Side effects of HIV therapy
BR112022014772A2 (pt) Dispersão sólida amorfa, composição farmacêutica e processos para a preparação destas
CL2022003426A1 (es) Composición farmacéutica acuosa de levilimab y su uso
BR112023020093A2 (pt) Conjugado anticorpo-fármaco, incluindo anticorpo contra cldn18.2 humano, e uso do mesmo
MA46778A1 (fr) Composition intranasale comprenant de la bétahistine
Huerta-Ramos et al. The effect of raloxifene on symptoms and cognitive functioning in a postmenopausal schizophrenia patient: a case report
Rodríguez-Martínez et al. Paliperidone extended-release: safety and tolerability from a metabolic profile perspective
Tanayen et al. Antidiabetic properties of an aqueous-methanolic stem bark extract of Spathodea campanulata (Bignoniaceae) P. Beauv
Nowak et al. New therapeutic strategies for Alzheimer’s disease
Syed et al. Fast dispersible tablet of paroxetine hydrochloride: taste masking and administration in depressed patients